- Home
- ENTA vs AIRS Comparison
ENTA vs AIRS Comparison
Compare ENTA & AIRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- AIRS
- Stock Information
- Founded
- ENTA 1995
- AIRS 2012
- Country
- ENTA United States
- AIRS United States
- Employees
- ENTA N/A
- AIRS N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- AIRS Medical/Nursing Services
- Sector
- ENTA Health Care
- AIRS Health Care
- Exchange
- ENTA Nasdaq
- AIRS Nasdaq
- Market Cap
- ENTA 164.6M
- AIRS 166.3M
- IPO Year
- ENTA 2013
- AIRS 2021
- Fundamental
- Price
- ENTA $10.85
- AIRS $10.85
- Analyst Decision
- ENTA Strong Buy
- AIRS Hold
- Analyst Count
- ENTA 5
- AIRS 2
- Target Price
- ENTA $21.00
- AIRS $3.75
- AVG Volume (30 Days)
- ENTA 554.0K
- AIRS 1.0M
- Earning Date
- ENTA 11-24-2025
- AIRS 10-31-2025
- Dividend Yield
- ENTA N/A
- AIRS N/A
- EPS Growth
- ENTA N/A
- AIRS N/A
- EPS
- ENTA N/A
- AIRS N/A
- Revenue
- ENTA $64,806,000.00
- AIRS $165,109,000.00
- Revenue This Year
- ENTA $0.07
- AIRS N/A
- Revenue Next Year
- ENTA N/A
- AIRS $5.14
- P/E Ratio
- ENTA N/A
- AIRS N/A
- Revenue Growth
- ENTA N/A
- AIRS N/A
- 52 Week Low
- ENTA $4.09
- AIRS $1.53
- 52 Week High
- ENTA $15.34
- AIRS $12.00
- Technical
- Relative Strength Index (RSI)
- ENTA 51.27
- AIRS 64.20
- Support Level
- ENTA $10.30
- AIRS $8.91
- Resistance Level
- ENTA $11.15
- AIRS $11.93
- Average True Range (ATR)
- ENTA 0.56
- AIRS 0.84
- MACD
- ENTA -0.17
- AIRS 0.05
- Stochastic Oscillator
- ENTA 19.19
- AIRS 71.04
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.